New insights into Mullerian inhibiting substance and its mechanism of action

Journal of Endocrinology

Volumn 158, Issue 1, 1998, Pages 1-6

  Lane, A H ^a   Donahoe, P K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR; MUELLERIAN INHIBITING FACTOR;

ANTINEOPLASTIC ACTIVITY; CRYPTORCHISM; HUMAN; MUELLERIAN DUCT; NONHUMAN; OVARY DEVELOPMENT; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SEXUAL DEVELOPMENT; SIGNAL TRANSDUCTION; TESTIS DEVELOPMENT;

ANIMALS; CATTLE; FEMALE; GENE EXPRESSION REGULATION; GLYCOPROTEINS; GROWTH INHIBITORS; HUMANS; MALE; MICE; MULLERIAN DUCTS; RATS; SEX DIFFERENTIATION; SIGNAL TRANSDUCTION; TESTICULAR HORMONES;

EID: 0031829302     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1580001     Document Type: Review

References (59)

1. Al-Attar L, Noel K, Dutertre M, Belville C, Forest MG, Burgoyne PS, Josso N & Rey R 1997 Hormonal and cellular regulation of Sertoli cell anti-Mullerian hormone production in the postnatal mouse. Journal of Clinical Investigation 100 1335-1343.
2. Baarends WM, Uilenbroek JT, Kramer P, Hoogerbrugge JW, van Leeuwen EC, Themmen AP & Grootegoed JA 1995 Anti-Mullerian hormone and anti-Mullerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. Endocrinology 136 4951-4962.
3. Behnnger RR, Gate RL, Froelick GJ, Palmiter RD & Brinster RL 1990 Abnormal sexual development in transgenic mice chronically expressing mullerian inhibiting substance. Nature 345 167-170.
4. Behnnger RR, Finegold MJ & Cate RL 1994 Mullerian-inhibiting substance function during mammalian sexual development. Cell 79 415-425.
5. Cate RL & Wilson CA 1993 Mullerian inhibiting substance. In Genes in Mammalian Reproduction, pp 185-205. Ed RBL Gwatkin. New York: Wiley-Liss.
6. Cate RL, Mattaliano RJ, Hession C, Tizard R, Farber NM, Cheung A, Ninfa EG, Frey AZ, Gash DJ, Chow EP, Fisher RA, Bertonis JM, Torres G, Wallner BP, Ramachandran KL, Ragin RC, Manganaro TF, MacLaughlin DT &. Donahoe PK 1986 Isolation of the bovine and human genes for Mullerian inhibiting substance and expression of the human genes in animal cells. Cell 45 685-698.
7. Cate RL, Donahoe PK & MacLaughlin DT 1990 Mullerian inhibiting substance. In Peptide Growth Factors and Their Receptors II, pp 179-210. Eds MB Sporn & AB Roberts. Berlin: Springer-Verlag.
8. Catlin EA, Manganaro TF & Donahoe PK 1988 Mullerian inhibiting substance depresses accumulation in vitro of disaturated phosphatidylcholine in fetal rat lung. American journal of Obstetrics and Gynecology 159 1299-1303.
9. Catlin EA, Powell SM, Manganaro TF, Hudson PL, Ragin RC, Epstein J & Donahoe PK 1989 Sex-specific fetal lung development and Mullerian inhabiting substance. American Review of Respiratory Disease 141 466-470.
10. Catlin EA, Tonnu VC, Ebb RG, Pasheco BA, Manganaro TF, Ezzell RM, Donahoe PK & Teixeira J 1997 Mullerian inhibiting substance inhibits branching morphogenesis and induces apoptosis in fetal rat lung. Endocrinology 138 790-796.
11. Chin T, Parry RL & Donahoe PK 1991 Human Mullerian inhibiting substance inhibits tumor growth in vitro and in vivo. Cancer Research 51 2101-2106.
12. diClemente N, Goxe B, Remy JJ, Cate RL, Josso N, Vigier B & Salesse R 1994 Effect of AMH upon aromatase activity and LH receptors of granulosa cells of rat and porcine immature ovaries. Endocrine 2 553-558.
13. Donahoe PK, Ito Y & Hendren WH 1977 A graded organ culture assay for the detection of Mullerian inhibiting substance. Journal of Surgical Research 23 141-148.
14. Dresser DW, Hacker A, Lovell-Badge R & Guerrer D 1995 The genes for a spliceosome protein (SAP62) and the anti-Mullerian hormone (AMH) are contiguous. Human Molecular Genetics 4 1613-1618.
15. Faure E, Gouedard L, Imbeaud S, Cate R, Picard JY, Josso N & di Clemente N 1996 Mutant isoforms of the anti-Mullerian hormone type II receptor are not expressed at the cell membrane. Journal of Biological Chemistry 271 30571-30575.
16. Franzen P, ten Dijke P, Ichijo H, Yamashita H, Schulz P, Heldin CH & Miyazono K 1993 Cloning of a TGF-β type I receptor that torms a heteromeric complex with the TGF-B type II receptor. Cell 75 681-692.
17. Giuili G, Shen WH & Ingraham HA 1997 The nuclear receptor SF1 mediates sexually dimorphic expression of Mullerian inhibiting substance, in vivo. Development 124 1799-1807.
18. Guerrier D, Tran D, Vanderwinden JM, Hideux S, Van Outryve L, Legeai L, Bouchard M, Van Vliet G, De Laet MH, Picard JY et al. 1989 The persistent Mullerian duct syndrome: a molecular approach. Journal of Clinical Endocrinology and Metabolism 68 46-52.
19. Gustafson ML, Lee MM, Scully RE & Moncure AC 1992 Mullerian inhibiting substance as a marker for ovarian sex-cord tumor. New England Journal of Medicine 326 466-171.
20. Haqq CM, King CY, Donahoe PK & Weiss MA 1993 SRY recognizes conserved DNA site in sex-specific promoters. Proceedings of the National Academy of Sciences of the USA 90 1097-1101.
21. Haqq CM, King CY, Ukiyama E, Falsafi S, Haqq TN, Donahoe PK & Weiss MA 1994 Molecular basis of mammalian sexual determination: activation of Mullerian inhibiting substance gene expression by SRY (published erratum appears in Science 1995 267 317) Science 266 1494-1500.
22. Harley VR, Lovell-Badge R & Goodfellow PN 1994 Definition of a consensus DNA binding site for SRY. Nucleic Acids Research 22 1500-1501.
23. He WW, Gufstafson ML, Hirobe S & Donahoe PK 1993 Developmental expression of four novel senne/threonine kinase receptors homologous to the activin/transforming growth factor-beta type II receptor family. Developmental Dynamics 196 133-142.
24. Hirobe S, He WW, Lee MM & Donahoe PK 1992 Mullenan inhibiting substance messenger ribonucleic acid expression in granulosa and Sertoli cells coincides with their mitotic activity. Endocrinology 131 854-862.
25. Hutson J, Davidson PM, Reece LA, Baker ML & Zhou B 1994 Failure of gubernacular development in the persistent Mullerian duct syndrome allows herniation of the testis. Pediatric Surgery International 9 544-546.
26. Hutson JM, Hasthorpe S & Heyns CF 1997 Anatomic and functional aspects of testicular descent and cryptorchidism. Endocrine Reviews 18 259-280.
27. Ikeda Y, Lala DS, Luo X, Kim E, Moisan MP & Parker KL 1993 Characterization of the mouse FTZ-F1 gene, which encodes a key regulator of steroid hydroxylase gene expression. Molecular Endocrinology 7 852-860.
28. Ikeda Y, Luo X, Abbud R, Nilson JH & Parker KL 1995 The nuclear receptor steroidogenic factor 1 is essential for the formation of the ventromedial hypothalamic nucleus. Molecular Endocrinology 9 478-486.
29. Imbeaud S, Belville C, Messika-Zeiton L, Rey R, di Clemente N, Josso N & Picard JY 1996 A 27 base-pair deletion of the anti-Mullerian type II receptor gene is the most common cause of the persistent Mullerian duct syndrome. Human Molecular Genetics 5 1269-1277.
30. Josso N, Picard JY & Tran D 1977 The anti-Mullerian hormone. Recent Progress in Hormone Research 33 117-160.
31. Kuroda T, Lee MM, Haqq CM, Powell DM, Manganaro TF & Donahoe PK 1990 Mullerian inhibiting substance ontogeny and its modulation by follicle-stimulating hormone in the rat testes. Endocrinology 127 1825-1832.
32. Lee MM & Donahoe PK 1993 Mullerian inhibiting substance: a gonadal hormone with multiple functions. Endocrine Reviews 14 152-164.
33. Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, Hasegawa Y, Noto RA, Schoenfeld D & MacLaughlin DT 1996 Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. Journal of Clinical Endocrinology and Metabolism 81 571-576.
34. Lee MM, Donahoe PK, Silverman BL, Hasegawa T, Hasegawa Y, Gustafson ML, Chang YC & MacLaughlin DT 1997 The infant with ambiguous genitalia: measurements of serum mullerian inhibiting substance in the evaluation of children with nonpalpable gonads. Current Therapy in Endocrinology and Metabolism 6 216-223.
35. Luo X, Ikeda Y & Parker KL 1994 A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell 77 481-490.
36. MacLaughlin DT, Hudson PL, Graciano AL, Kenneally MK, Ragin RC, Manganaro TF & Donahoe PK 1992 Mullerian duct regression and anti-proliferative properties of Mullerian inhibiting substance reside in its carboxy-terminal domain. Endocrinology 131 291-296.
37. Massague J 1990 The transforming growth factor-β family. Annual Review of Cell Biology 6 597-641.
38. Massague J, Attisano L & Wrana JL 1994 The TGF-β family and its composite receptors. Trends in Cell Biology 4 172-178.
39. Miller HC & Futrakul P 1968 Birth weight, gestational age, and sex as determining factors in the incidence of respiratory distress syndrome of prematurely born infants. Journal of Pediatrics 72 628-635.
40. Mishina Y, Rey R, Finegold MJ, Matzuk MM, Josso N, Cate RL & Behringer RR 1996 Genetic analysis of the Mullerian-inhibiting substance signal transduction pathway in mammalian sexual differentiation. Genes and Development 10 2577-2587.
41. Munsterberg A & Lovell-Badge R 1991 Expression of the mouse anti-Mullerian hormone gene suggests a role in both the male and female sexual differentiation. Development 113 613-625.
42. Nachtigal M & Ingraham HA 1996 Bioactivation of Mullerian inhibiting substance during gonadal development by a kex2/subtilisin-like endoprotease. Proceedings of the National Academy of Sciences of the USA 93 7711-7716.
43. Parry RL, Chin TW, Epstein J, Hudson PL, Powell DM & Donahoe PK 1992 Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo. Cancer Research 52 1182-1186.
44. Pepinsky RB, Sinclair LK, Chow EP, Mattliano RJ, Manganaro TF, Donahoe PK & Cate RL 1988 Proteolytic processing of Mullerian inhibiting substance produces a transforming growth factor-β-like fragment. Journal of Biological Chemistry 263 18961-18964.
45. Powell JL & Otis CN 1997 Management of advanced juvenile granulosa cell tumor of the ovary. Gynecologic Oncology 64 282-284.
46. Rey RA, Lhomme C, Marcillac I, Lahlou N, Duvillard P, Josso N & Bidart JM 1996 Anti-Mullerian hormone as a serum marker of granulosa cell tumors of the ovary: comparative study with serum alpha inhibin and estradiol. American Journal of Obstetrics and Gynecology 174 958-965.
47. Shen WH, Moore CC, Ikeda Y, Parker KL & Ingraham HA 1994 Nuclear receptor steroidogenic factor 1 regulates the Mullerian inhibiting substance gene: a link to the sex determination cascade. Cell 77 651-661.
48. Taguchi O, Cunha GR, Lawrence WD & Robboy SJ 1984 Timing and irreversibility of Mullerian duct inhibition in the embryonic reproductive tract of the human male. Developmental Biology 106 394-398.
49. Takahashi M, Koide SS & Donahoe PK 1986 Mullerian inhibiting substance as oocyte meiosis inhibitor. Molecular and Cellular Endocrinology 47 223-234.
50. Taketo T, Saeed J, Manganaro T, Takahashi M & Donahoe PK, 1993 Mullerian inhibiting substance production associated with loss of oocytes and testicular differentiation in the transplanted mouse XX gonadal primordium. Biology of Reproduction 49 13-23.
51. Teixeira J & Donahoe PK 1996a Molecular biology of MIS and its receptors. Journal of Andrology 17 336-341.
52. Teixeira J, He WW, Shah PC, Morikawa N, Lee MM, Catlin EA, Hudson PL, Wing J, MacLaughlin DT & Donahoe PK 1996b Developmental expression of a candidate Mullerian inhibitory substance type II receptor. Endocrinology 137 160-165.
53. Torday JS, Nielsen HC, Fencl M & Avery ME 1981 Sex differences in fetal lung maturation. American Review of Respiratory Diseases 123 205-208.
54. Tsuji M, Shima H, Yonemura CY, Brody J, Donahoe PK & Cunha GR 1992 Effect of human recombinant Mullerian inhibiting substance on isolated epithelial and mesenchymal cells during Mullerian duct regression in the rat. Endocrinology 131 1481-1488.
55. Ueno S, Kuroda T, MacLaughlin DT, Ragin RC, Manganaro TF & Donahoe PK 1989a Mullerian inhibiting substance in the adult rat ovary during various stages of the estrous cycle. Endocrinology 125 1060-1066.
56. Ueno S, Takahashi M, Manganaro TF, Ragin RC & Donahoe PK 1989b Cellular localization of Mullerian inhibiting substance in the developing rat ovary. Endocrinology 124 1000-1006.
57. Wang T, Donahoe PK & Zervos AS 1994 Specific interaction of type I receptors of the TGF-β family with the immunophilin FKBP-12. Science 265 674-676.
58. Wang T, Danielson P, Li B-Y, Shah P, Kim S & Donahoe P 1996 The p21ras farensyltramferase alpha subunit in TGF-β and activin signaling. Science 271 1120-1122.
59. Zon LI, Youssoufian H, Mather C, Lodish HF & Orkin SH 1991 Activation of the erythropoeitin receptor promoter by transcription factor GATA-1. Proceedings of the National Academy of Sciences of the USA 88 10638-10641.